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Spa treatment for primary fibromyalgia syndrome:
a combination of thalassotherapy, exercise
and patient education improves symptoms
and quality of life
T. R. Zijlstra1, M. A. F. J. van de Laar1,2, H. J. Bernelot Moens1,
E. Taal2, L. Zakraoui3 and J. J. Rasker1,2
Objectives. To study the effect of a combination of thalassotherapy, exercise and patient education in people with fibromyalgia.
Methods. Patients with fibromyalgia, selected from a rheumatology out-patient department and from members of the Dutch
fibromyalgia patient association, were pre-randomized to receive either 2½ weeks of treatment in a Tunisian spa resort,
including thalassotherapy, supervised exercise and group education (active treatment) or treatment as usual (control treatment).
Primary outcome measure was health-related quality of life, measured with the RAND-36 questionnaire. Secondary measures
included the Fibromyalgia Impact Questionnaire, the McGill Pain Questionnaire, the Beck Depression Inventory, tender point
score and a 6-min treadmill walk test.
Results. Fifty-eight participants receiving the active treatment reported significant improvement on RAND-36 physical
and mental component summary scales. For physical health, differences from the 76 controls were statistically significant after
3 months, but not after 6 and 12 months. A similar pattern of temporary improvement was seen in the self-reported secondary
measures. Tender point scores and treadmill walk tests improved more after active treatment, but did not reach significant
between-group differences, except for walk tests after 12 months.
Conclusions. A combination of thalassotherapy, exercise and patient education may temporarily improve fibromyalgia
symptoms and health-related quality of life.
KEY WORDS: Fibromyalgia, Thalassotherapy, Exercise, Health-related quality of life.
Introduction
Fibromyalgia (FM) is a syndrome characterized by chronic
widespread musculoskeletal pain and increased tenderness to
palpation. Apart from these core symptoms, several additional
symptoms such as fatigue, stiffness, disturbed sleep, subjective
joint swelling, psychological distress and impaired cognitive func-
tion are considered part of the syndrome [1]. No factor has
been identified as the single cause of FM; a multifactorial model is
used to describe how various biological and psychosocial factors
can contribute to the onset and persistence of chronic pain [2].
Although the concept of FM and its validity as a clinical entity
remain the subject of debate [3], it has been recognized that FM has
a major impact on health status, quality of life, functional and
employment status, use of health-care resources and costs [4–7].
These findings highlight the need for an effective therapy, but at
present no curative treatment for FM is available.
Many studies have focused on self-management strategies, such
as patient education, coping skills training and physical exercise [8].
Although these strategies often prove to be superior to placebo
treatment, the relevance of their effects remains unclear.
Nevertheless, there is a growing tendency to offer multidisciplinary
treatment programmes for FM, based on the assumption that
combining different types of non-pharmacological therapy will
increase and prolong their positive effects [9–13].
In a prospective study on pain and pain relief in FM, Canadian
patients reported that exercise, relaxation, baths and massage
were the interventions most commonly preferred [14]. These four
interventions are also the basic ingredients of treatment courses in
spa resorts. Although spa therapy—bathing in thermal water—has
a long history in the treatment of various rheumatic diseases,
its effects have not been studied properly [15]. In FM, minor
improvements in pain intensity have been reported after balneo-
therapy, using thermal water [16], plain water with or without
herbal oils [17] or hydrogalvanic baths [18]. However, small patient
numbers and methodological shortcomings limit the validity of
these data. In a randomized controlled trial, 24 FM patients
receiving balneotherapy at the Dead Sea showed significant
improvement in quality of life for at least 3 months. However,
24 controls who stayed in the same area without receiving
balneotherapy also improved, albeit to a lesser extent [19].
Individual FM patients have reported beneficial effects from
thalassotherapy, a form of spa treatment in which sea water, algae
and the seaside climate are applied as therapeutic ingredients [20,
21]. Though not supported by scientific evidence, thalassotherapy
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is practised in many Mediterranean countries, especially France,
where it is applied in the treatment of various conditions.
The aim of the present study was to assess the effects of a group
programme of thalassotherapy, exercise and self-management
education in patients with FM, both in terms of FM-related
symptoms and of health-related quality of life.
Patients and methods
Subjects
People with primary fibromyalgia syndrome (FMS) were included
if they fulfilled the following criteria: a diagnosis of primary FMS
made by a rheumatologist, according to the ACR 1990 classifica-
tion criteria [22]; age between 18 and 65 yr; willingness to undergo
an in-patient treatment of some weeks. Exclusion criteria were:
secondary FMS (i.e. presence of another underlying disease that
causes chronic widespread pain); co-morbidity interfering with spa
treatment; other serious co-morbidity; dependency on a wheelchair
or help from other people; current involvement in a law pro-
cedure concerning disability or employment; recent spa treatment
for musculoskeletal disorders; difficulty understanding Dutch.
Study design
The study was designed as a pre-randomized controlled trial.
Obviously, patients could not be blinded for the intervention.
Knowledge of being either in the spa treatment group or in the
control group might considerably influence the results. In order
to reduce this patient-related bias, patients were not informed of
the comparison between groups. A modified pre-randomized study
design according to Zelen [23] was applied, in which the consent-
before-randomization sequence was reversed. Patients eligible
for inclusion were randomly allocated to the treatment or control
group using a computer-generated randomization list and closed
numbered envelopes. Patients allocated to the spa treatment group
(SPA) were then fully informed about the spa treatment and the
corresponding study protocol. Patients allocated to the control
group (CTL) received only information about their part of the
study protocol which was described as a study of the social
consequences of FM. They were not told that they formed a
control group for an intervention study. Moreover, to maintain
this patient blinding, patients in the SPA group were specifically
asked not to talk to other patients about the study. They were
instructed to inform only their spouses, close relatives and
(if necessary) their employer.
The pre-randomized study design carries the risk of selection
bias. In our study, for instance, employed patients or patients with
small children may find it more difficult to leave their job or their
family for 2½ weeks. Therefore patients in the SPA group are
more likely to refuse participation than CTL patients. To prevent
this type of selection bias, the following question was included
in the screening questionnaire: ‘If a few weeks’ admission to
a rehabilitation centre would be useful for treating your fibro-
myalgia, would you be prepared to do so?’ If the answer was ‘no’,
the person was excluded. After discussing the specific ethical issues
raised by the pre-randomized design, the study was approved
by the Medical Ethical Committee of Medisch Spectrum Twente
Hospital, Enschede, The Netherlands. All participants gave written
informed consent.
Patient selection
Two comparable methods of patient selection were applied. First,
from our Diagnosis Registry we selected all patients aged between
18 and 65, who had visited one of our regional rheumatology
clinics in 1997 or 1998 and in whom a clinical diagnosis of FMS
had been made. Eligible cases were sent a letter asking the patient
to ‘participate in a study on the social consequences of FM’.
Second, through an advertisement in the Dutch FM patient
association (FES) magazine (with 10 000 members at that time),
patients were asked to ‘participate in a study on the social
consequences of FM’. All patients interested in the study were
asked to answer a screening questionnaire and return it by mail.
If their answers to this questionnaire revealed no apparent reasons
for exclusion, they were seen by the investigator (TRZ), who after
an interview and physical examination decided if patients were
eligible for inclusion.
Intervention
Treatment groups consisted of 17–21 patients. They were
accompanied by three people: the principal investigator (TRZ,
a rheumatologist), a sports instructor and a FM patient familiar
with thalassotherapy. Some weeks before the journey a group
meeting was arranged to make each other’s acquaintance and to
give information about the journey, the spa treatment and the
follow-up. Participants were required to contribute E227 (or less if
they could not afford this), covering a small part of the total cost
of travel and accommodation. The spa treatment was given
on Jerba, a peninsula off the coast of southern Tunisia with a
temperate Mediterranean climate. The first group went in
March–April 1999, the second and third groups in May and
June 2000. On day 1 patients travelled to Jerba by air. They stayed
in a luxurious tourist hotel on a full-board basis, sharing rooms
with a fellow patient. Spouses or relatives were not allowed to join
them. On day 19 the group returned home. The treatment
programme consisted of four elements: thalassotherapy, exercise,
patient education and recreational activities.
Thalassotherapy was provided in a thalassocentre, a well-
equipped institute located within the hotel complex. Its Tunisian
staff are well-trained and maintain high standards of hygiene
and service. On day 2, before starting thalassotherapy, patients
were seen by the spa doctor, who composed a therapy programme
according to their individual demands. The programme consisted
of seven or eight sessions divided over 15 days. Each session
included four out of the following modalities: hamam (Turkish
bath), algotherapy (hot packs with algae), douche a` affusion
(massage while lying under a shower), whirlpool, underwater
jetstream massage, pool exercise and massage. The different
treatment modalities alternated with resting periods; a complete
thalassotherapy session took approximately 3 hours. If patients
experienced adverse effects or other problems related to thalas-
sotherapy, their programme was adjusted in consultation with the
spa doctor.
A series of seven 1-hour sessions of supervised group exercise
was scheduled on days when no thalassotherapy was given.
Exercise groups consisted of four or five persons. The exercise
programme included warming-up, gentle stretching and various
forms of low-impact aerobic exercise, e.g. treadmill walking, cycl-
ing and swimming. Patients were instructed to exercise within
their own abilities, trying to reach 70% of the predicted maximum
heart rate for their age (beats per minute¼ 220 age). Apart from
the supervised exercise sessions, participants were encouraged
to start each day with 20–30min of swimming and to take some
form of light exercise (e.g. walking on the beach or recreational
swimming) on mornings or afternoons with no formally scheduled
thalassotherapy or exercise sessions.
The patient education programme consisted of seven sessions
of 1–1½hours, directed by the rheumatologist (TRZ). The first
and seventh sessions were plenary sessions, the other sessions were
in smaller groups of approximately 10 persons. The programme
was a mixture of lectures by the rheumatologist, plenary discus-
sions and discussions in small groups, and small assignments to
be prepared before the next session. The following issues were
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included: general information on FM; importance of physical
fitness and exercise; the role of emotions in FM; finding a balance
between workload and capacity; stress handling; coping with
reactions from others; sense and nonsense about drugs, diets,
complementary and alternative medicine. Patients were encour-
aged to share their experiences, but mere complaining was
gradually restricted, whereas positive coping styles and practical
problem-solving were emphasized. Elements of self-management
programmes were applied [24], based on the self-efficacy theory of
Bandura [25].
Recreational facilities were available according to the standards
for luxurious tourist hotels. They included indoor and outdoor
swimming pools, a sandy beach, day trips and a range of other day-
and night-time entertainment.
Although recreational and tourist activities were part of the
programme, instructions for participants emphasized that they
should join in the treatment programme, and not just treat it as
a holiday. They were strongly advised to take adequate rest after
lunchtime and at night.
Control condition
Control (CTL) subjects were told they were participating in an
observational study to assess the impact of FM on several aspects
of health and social functioning. They continued treatment as
usual, provided by their own physicians.
Assessments
At baseline (1 week before travelling to Jerba) the SPA subjects
answered a set of several self-administered questionnaires (see
below). At the beginning and the end of their stay in the spa resort,
a tender point examination and a physical fitness test were per-
formed. In the second week after their return patients answered
the same set of questionnaires. At 3, 6 and 12 months, tender point
examination and physical fitness testing as well as questionnaires
were repeated. CTL subjects were assessed with the same instru-
ments at baseline and after 3, 6 and 12 months. They were not
assessed after 1 month, since this might have appeared rather
irrational to them.
General health status, measured with the RAND 36-item health
survey (RAND-36), was chosen as the primary outcome measure.
The RAND-36 bas been translated and validated for use in Dutch
patients [26]. It is almost identical to the SF-36, which is universally
applied in studies of various chronic disorders. The SF-36 had
sufficient sensitivity to change in a study of cognitive behavioural
therapy and in a study of balneotherapy for FMS [19, 27].
Two summary components were computed, aggregating scores
from eight subscales of the RAND-36 into two summary scores:
Physical Component Summary (PCS or physical health) and
Mental Component Summary (MCS or mental health) [28].
Raw scale scores of the RAND-36 were transformed into Z scores,
using Dutch means and standard deviations [29], which were
multiplied with the US factor score coefficients and summed
over all eight subscales (US factor scores were used to facilitate
international comparisons). Finally, t-scores were calculated by
multiplying the obtained PCS and MCS sums by 10 and adding
50 to the product to obtain transformed summary scores that
are normally distributed with a mean of 50 and a standard
deviation of 10 [28]. General health was also measured with a
100-mm visual analogue scale (VAS) for general health during
the past week.
Disease specific health status was measured with a Dutch
translation of the Fibromyalgia Impact Questionnaire (FIQ).
The FIQ is a validated self-report inventory which has been
recommended as a primary endpoint in FM clinical trials [30, 31].
Respondents are requested to rate their status within the past
week. Questions 1–10, rated on a four-point adverbial rating
scale, are summed to form one subscore for physical impairment.
Item 11 asks for the number of days on which one felt good,
item 12 asks how many days of work were missed because
of fibromyalgia. Items 13–19, dealing with job difficulty, pain,
daytime fatigue, morning tiredness, stiffness, anxiety and depres-
sion, are rated on a 100-mm VAS. Results for each item are
normalized to yield a score between 0 and 10, with higher scores
indicating greater impairment. FIQ total score is computed by
summing all except the two job-related items, thus ranging
from 0 to 80.
The FIQ has been translated into various languages [32–36],
but our Dutch translation has not been formally validated yet.
Therefore a number of other validated, frequently used outcome
measures were included to study individual domains of the FIQ.
Depression was measured using a Dutch translation of the 1979
version of Beck’s Depression Inventory (BDI) [37, 38]. Pain was
assessed using the McGill Pain Questionnaire—Dutch Language
Version (MPQ-DLV) [39]. Fatigue was measured with the
subscales ‘subjective fatigue’ and ‘physical activity’ of the
Checklist Individual Strength (CIS) [40]. This instrument asks
respondents to judge a set of statements concerning their fatigue
on a seven-point adjectival rating scale from 1 (¼correct) to 7
(¼incorrect). The CIS has been validated as a measure of fatigue
in different patient populations. Sleep problems are frequently
mentioned as part of FMS, but are not included as an item in
the FIQ. To assess sleep quality, a separate 100-mm VAS for sleep
over the past week was added to the questionnaire.
Tender points were examined by applying a pressure of
approximately 4 kg with the tip of the thumb or index finger on
the 18 points defined in ACR classification criteria [22]. From this
assessment the total number of painful tender points (tender point
score, TPS; range 0–18) and a graded tender point score (GTPS)
were recorded. For GTPS each point was scored by the assessor
on a scale from 0 to 3 (0, no pain; 1, mild pain, no grimace; 2,
spontaneous verbal reaction to pain and grimace; 3, severe pain
with withdrawal) and the sum of 18 points was recorded [41, 42].
Patients and controls were all assessed by the same observer
(TRZ).
Physical fitness was measured with a modified 6-min walk
test. Patients walked on a computerized treadmill system
(TechnogymTM Runrace HC-1200) with automatic heart rate
monitoring (PolarTM) for 8min. They were constantly supervised
and received instructions on how to walk without leaning on the
handlebars and how to maintain a normal walking pace. During
the first 2min the treadmill system automatically adjusted its speed
and slope, until the patient reached the target heart rate of
0.70 (220  age)/min. The treadmill speed did not exceed normal
walking pace, thus allowing all patients to perform at their own
level without actually having to run. From speed, slope and
the patient’s weight the system computed the amount of labour
performed. Labour during the last 6min was recorded as a measure
of physical fitness. Using this procedure, the test result was
independent of patient motivation or perceived exertion.
Statistical analysis
Demographic characteristics of SPA and CTL groups were
compared with the 2 test (binary data), Mann–Whitney test
(ordinal data) or two-tailed independent t-test (continuous data).
Results of SPA subjects after 1 month were compared to baseline
using the paired-samples t-test orWilcoxon signed ranks test. Since
control patients were not assessed after 1 month, between-group
comparison at that time was not performed. For the primary
outcome measure (RAND-36) results at 3, 6 and 12 months
were analysed by univariate analysis of covariance (ANCOVA)
with baseline values as covariate. Before applying ANCOVA the
assumptions for performing ANCOVA (homogeneity of variance
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and parallelism of regression) were checked. For FIQ total score
and all other outcomes, results at 3, 6 and 12 months were analysed
by comparing change scores between groups, using the two-tailed
independent-sample t-test or theMann–Whitney test (change score
Tx¼ value Tx  value To).
Results
Results of patient selection and randomization are presented
in Fig. 1. A total of 170 patients initially fulfilled inclusion criteria;
84 of them were randomized into the SPA and 86 into the
CTL group. After randomization and information, more patients
refused participation in the SPA group than in the CTL group.
Reasons for refusal in the SPA group were: three job related,
six family related, two financial, 12 unknown. In the CTL group
these were: one marked improvement of FM symptoms, one
disappointment with the study protocol, six unknown. Three SPA
and two CTL subjects withdrew due to co-morbidity occurring
in the period between inclusion and study start. Finally, 58 patients
received spa treatment and 76 patients entered the control
protocol. Baseline demographic characteristics for both groups
are shown in Table 1. No statistically significant group differences
were found.
During follow-up, the response rate by self-reported question-
naire was high: 95.3% for SPA and 95.6% for CTL. Only one SPA
subject withdrew from follow-up after 6 months; several attempts
were made to contact her, but she did not respond or return
the remaining questionnaires. Although all CTL subjects con-
tinued to return their questionnaires (by mail if necessary), their
overall rate of attendance at the follow-up visits was lower: 80.3%
for CTL vs 89.1% for SPA. All but one of the CTL subjects
remained unaware of the fact that they were controls for a spa
treatment group.
Following treatment, SPA subjects reported significant
improvement in mental and physical component summary scores
(Table 2) and on all subscales of the RAND-36 (data not shown).
After 3 months, the differences between SPA and CTL were
statistically significant for physical but not for mental health. After
6 and 12 months, no statistically significant differences between
SPA and CTL were found.
Results of FIQ subscales and total score are presented in
Table 3. At baseline there were no statistically significant
differences between SPA and CTL. At T¼ 1 month the SPA
group showed improvement on FIQ total score (P 0.01 for the
paired-sample t-test) and on all individual items, except ‘days
missed work’. After 3 months, improvements were less pro-
nounced, but differences between FIQ total score of SPA and
CTL were statistically significant. After 6 months, change scores
in the SPA group still suggested improvement, but differences
from CTL were not statistically significant. After 12 months,
few differences in favour of the SPA group remained, whereas
SPA subjects even scored somewhat higher on depression.
Results of other outcome measures are summarized in Table 4.
BDI scores for depression improved in the SPA group shortly after
treatment, but during follow-up no significant difference between
SPA and CTL was seen. The same applies to outcomes of VAS
sleep. The MPQ-DLV total pain rating index decreased by 35%
after spa treatment; at T¼ 3 months change scores in the SPA
group were still significantly larger than in the CTL group. The CIS
subscale ‘subjective fatigue’ improved by 26% after spa treatment;
the difference between SPA and CTL remained statistically
significant for 6 months. Improvement on the subscale ‘activity’
was less pronounced. VAS ratings of general health in the SPA
group initially improved by 26%. This improvement had been
halved after 3 months and disappeared after 6 months. Tender
points significantly decreased after spa treatment, both in terms of
number and severity. However, this also occurred in the CTL
group, though more gradually. Therefore change scores only
differed significantly between groups at T¼ 3 months. Finally,
SPA and CTL groups both performed better on the treadmill walk
test during follow-up than at baseline. Differences between groups
were statistically significant at the 12 month assessment only.
SPA subjects were overall very satisfied with thalassotherapy.
Minor adverse events such as sunburn and mild self-limiting
gastroenteritis occurred frequently, as might be expected in
a Mediterranean environment, and caused some patients to
patients seen for inclusion
280
excluded
110
refused
23
refused
8
new comorbidity
3
treatment
58
informed consent
randomized to treatment
84
new comorbidity
2
controls
76
informed consent
randomized to control
86
eligible for randomisation
170
no response
86
refused to participate
39
excluded by questionnaire
32
seen by investigator
110
request to FM outpatients
267
regional
no response
?
not able to contact or visit
71
excluded by questionnaire
95
seen by investigator
170
readers of FES Magazine
?
nationwide
FIG. 1. Flow chart of patient selection and randomization.
TABLE 1. Baseline demographic data of spa treatment (SPA) and control
(CTL) groups
SPA CTL
No. of patients (female:male) 58 (55:3) 76 (73:3)
Age (yr), median (range) 48 (22–64) 47 (24–64)
Married or living with a partner (%) 44 (76) 66 (87)
Years since continuous symptoms
onset, median (range)
10 (2–35) 10 (1–42)
Educational level, median (range)a 3 (1–6) 3 (1–6)
Employment status
Employed (%) 24 (41.4) 27 (35.5)
Health-related unemployment (%) 25 (43.1) 32 (42.1)
Other reasons for unemployment (%) 9 (15.5) 17 (22.4)
aMaximum possible range is 1 (elementary school)–6 (university).
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occasionally skip a thalassotherapy session. Two patients experi-
enced more significant adverse events, although these were not
strictly related to thalassotherapy. One of them sprained an ankle
while visiting a nearby village. The other patient was examined
in a local hospital after falling off a horse. She sustained only
superficial injuries and could return to the hotel after tetanus
vaccination. In the remaining week she followed an adjusted
regimen of thalassotherapy and exercise.
Discussion
The results of this study confirm our hypothesis that a combination
of thalassotherapy, exercise and patient education can significantly
improve symptoms and health-related quality of life in FM. After
3–6 months, most outcome measures showed improvement.
After 6 months, however, most differences between SPA and
CTL group were no longer statistically significant, indicating that
TABLE 3. Results of Fibromyalgia Impact Questionnaire
Change from baseline
FIQ subscales Baseline value To T¼ 1 month T¼ 3 months T¼ 6 months T¼ 12 months
Physical functioning
Spa 4.5 (1.7) 0.9 (1.6) 0.6 (1.4) 0.3 (1.6) 0.1 (1.8)
Control 4.5 (1.6) 0.0 (1.4) 0.1 (1.5) 0.2 (1.5)
Days not feeling good
Spa 7.2 (2.4) 3.0 (1.2) 1.3 (3.1) 0.4 (3.1) 1.0 (2.6)
Control 6.6 (2.7) 0.1 (2.7) 0.1 (2.6) 0.4 (3.2)
Days missed work
Spa 0.9 (2.2) 0.4 (1.2) 0.8 (2.3) 0.5 (3.5) 1.1 (3.8)
Control 0.8 (2.6) 0.7 (1.9) 1.2 (3.4) 1.5 (3.1)
VAS job difficulty
Spa 5.7 (2.2) 1.5 (2.8) 0.9 (2.6) 0.2 (3.0) 0.3 (2.1)
Control 5.7 (2.1) 0.0 (2.0) 0.1 (2.1) 0.0 (2.6)
VAS pain
Spa 5.9 (1.8) 1.6 (2.3) 0.7 (1.9) 0.1 (2.3) 0.1 (1.7)
Control 5.8 (1.7) 0.0 (1.5) 0.1 (1.7) 0.3 (1.9)
VAS fatigue
Spa 6.5 (2.0) 1.6 (2.8) 1.0 (2.0) 0.8 (2.5) 0.3 (2.1)
Control 6.3 (1.9) 0.1 (1.7) 0.1 (1.6) 0.3 (2.0)
VAS morning tiredness
Spa 6.6 (1.9) 1.5 (2.6) 0.9 (2.2) 0.3 (2.5) 0.1 (2.1)
Control 6.2 (2.3) 0.0 (2.3) 0.3 (2.0) 0.1 (2.7)
VAS stiffness
Spa 6.3 (2.1) 1.9 (2.7) 0.8 (2.0) 0.3 (2.3) 0.5 (1.9)
Control 6.4 (2.0) 0.4 (1.7) 0.1 (1.7) 0.5 (1.9)
VAS depression
Spa 2.6 (2.4) 0.7 (2.1) 0.2 (2.4) 0.1 (2.4) 0.6 (2.8)
Control 2.8 (2.3) 0.1 (2.1) 0.1 (2.2) 0.3 (2.4)
VAS anxiety
Spa 3.7 (2.8) 1.3 (2.7) 0.6 (2.7) 0.5 (2.7) 0.2 (3.0)
Control 3.4 (2.4) 0.2 (2.0) 0.1 (2.3) 0.4 (2.0)
FIQ total score (range 0–80)
Spa 43.2 (11.9) 12.8 (12.9)* 6.3 (11.4)** 2.6 (13.8) 1.7 (10.8)
Control 42.3 (11.6) 0.9 (10.2) 0.3 ( 9.2) 2.5 (12.0)
Data are presented as mean scores (S.D.) at baseline and mean change from baseline (S.D.) at follow-up assessments. Raw data were transformed into
normalized scores, all ranging from 0 to 10, with higher scores indicating a worse condition. Negative change indicates improvement.
*P<0.01 for SPA group between baseline and T¼ 1 month.
**P<0.01 for difference between SPA and CTL group.
TABLE 2. Results of RAND-36
Change from baseline
RAND-36 components Baseline value To T¼ 1 month T¼ 3 months T¼ 6 months T¼ 12 months
Physical component
Spa 28.6 (8.0) 6.3 (8.2)* 3.6 (8.8)** 1.3 (9.6) 2.6 (7.4)
Control 27.8 (7.4) – 0.8 (6.7) 0.5 (5.8) 1.6 (7.8)
Mental component
Spa 45.7 (11.5) 6.5 (10.2)* 0.8 (11.2) 0.2 (9.8) 2.2 (11.1)
Control 46.5 (10.2) – 1.2 (9.1) 0.1 (11.4) 0.5 (10.1)
Data are presented as mean scores (S.D.) at baseline and mean change from baseline (S.D.) at follow-up assessments. Maximum range for each item is
0–100. Positive change indicates improvement.
*P<0.001 for post-spa change from baseline (paired t-test).
**P¼ 0.02 for spa vs control (ANCOVA).
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our combined programme should be regarded as a palliative
treatment with temporary effects.
A randomized controlled trial is generally considered the best
way to study the effect of an intervention. Had we used a
conventional RCT design in the present study, then patients
allocated to the CTL group would probably have been very
disappointed and hence would have withdrawn or be negatively
influenced. To avoid this, a pre-randomized design was chosen,
allowing us to keep CTL subjects unaware of the treatment
condition. Obviously SPA subjects could not be blinded to the
treatment, so results may have been influenced by suggestion or by
a ‘desire to please the observer’.
Our pre-randomized design carried a risk of selection bias,
as would have been the case for a conventional randomized
controlled trial. We tried to avoid this by excluding in advance
those who objected to admission to a rehabilitation clinic for
FM. The resemblance of patient characteristics in the SPA and
CTL groups indicates that major selection bias did not occur.
The 1-month assessment for SPA subjects was included to evaluate
short-term effects. We chose not to assess CTL subjects after
1 month, therefore no direct comparison between SPA and
CTL group for that interval could be made.
Our results suggest that the positive effects of spa treatment
extend to several domains, including general health, pain, fatigue
and physical functioning, which are all very relevant in FM. The
same pattern of improvement occurs in various outcome measures,
indicating that positive outcomes are not a result of multiple test-
ing but reflect actual health improvement.
Improvement in mental health was less pronounced and of
shorter duration than in physical health, suggesting that our
treatment programme exerts predominantly physical effects. We
would like to mention, however, that the rather low baseline
levels of depression in our study sample left only limited room
for improvement. In our study mean VAS depression was 27mm
and mean BDI 13.1, whereas other studies reported 42 to
66mm for VAS depression [9, 10, 13] and 16 to 22 for BDI
[10, 11, 43].
The results from the 6-min walk tests at 3- and 6-month intervals
suggest improvement of physical fitness in both groups. Two and
a half weeks of exercise training may generally be considered too
short to improve physical fitness. However, most exercise studies in
FM have applied exercise frequencies of two to three times 1 hour
per week [44, 45–47], whereas our patients exercised on a daily
basis. Additionally, the patient education programme may have
encouraged them to continue exercising at home. Maybe this
explains why, after 12 months, the SPA group performed signi-
ficantly better on the walk test. However, these results must be
interpreted with caution.
There was a significant difference in tender point scores between
SPA and CTL subjects after 3 months. At longer follow-up,
however, this difference diminished, mainly because tender point
scores in the CTL group gradually decreased. This is in line with
findings from Dunkl et al. [31], who showed that in patients
reporting worse or unchanged symptoms over a 6-month period,
the tender point count still decreased by 0.62 and 0.91 points
respectively. A possible explanation for this finding might be that
TABLE 4. Results of other outcome measures
Baseline value
Change from baseline
Instrument (range) To T¼ 1 month T¼ 3 months T¼ 6 months T¼ 12 months
BDI total score (0–63)
Spa 13.2 (6.8) 2.9 (3.8)* 1.7 (5.5) 2.0 (4.5) 0.3 (5.5)
Control 13.0 (6.7) 1.2 (5.3) 0.8 (5.4) 0.8 (4.7)
MPQ-DLV pri-total (0–63)
Spa 21.1 (8.4) 7.3 (8.3)* 4.0 (7.3)*** 2.8 (8.5) 1.4 (6.9)
Control 21.0 (8.8) 2.5 (8.6) 2.0 (8.3) 1.5 (7.9)
CIS subjective feeling (8–56)
Spa 45.2 (8.7) 11.6 (11.0)* 5.5 (9.1)*** 3.6 (9.4)**** 2.8 (9.5)
Control 44.0 (8.2) 1.4 (6.5) 0.2 (7.4) 1.3 (8.2)
CIS activity (3–21)
Spa 12.0 (6.1) 1.8 (5.3)** 0.8 (3.8)**** 0.0 (4.5) 0.7 (5.5)
Control 10.9 (5.3) 1.1 (4.9) 1.6 (4.8) 0.7 (5.4)
VAS sleep (0–10)
Spa 5.5 (2.1) 1.5 (2.8)* 0.1 (2.2) 0.1 (2.5) 0.4 (2.5)
Control 5.9 (2.2) 0.3 (2.3) 0.1 (2.3) 0.4 (2.5)
VAS general health (0–10)
Spa 6.1 (1.8) 1.6 (2.6)* 0.8 (2.2)**** 0.0 (2.3) 0.1 (1.9)
Control 6.2 (1.6) 0.2 (1.7) 0.1 (1.7) 0.5 (1.8)
No. of tender points (0–18)
Spa 13.8 (2.5) 2.2 (2.8)* 2.0 (3.4)*** 1.2 (3.3) 1.9 (3.8)
Control 13.6 (2.6) 0.6 (2.2) 1.0 (2.8) 1.7 (3.1)
GTPS (0–54)
Spa 20.0 (7.5) 4.0 (6.0)* 3.6 (6.2)*** 1.7 (6.9) 2.6 (7.8)
Control 18.5 (5.3) 0.2 (3.9) 0.7 (4.7) 1.5 (5.5)
Treadmill walk test (kCal)
Spa 26.6 (9.0) 2.9 (7.3)* 5.9 (8.3) 5.7 (10.2) 5.1 (7.6)****
Control 28.0 (9.2) 3.3 (6.8) 4.4 (6.9) 1.7 (6.7)
Data are presented as mean scores (S.D.) at baseline and mean change from baseline (S.D.) at follow-up assessments. Negative change indicates
improvement, except for treadmill walk test.
BDI, Beck Depression Inventory; MPQ-DLV, McGill Pain Questionnaire—Dutch Language Version; PRI, Pain Rating Index; CIS, Checklist
Individual Strength; GTPS, Graded Tender Point Score.
*P<0.01 for SPA group between baseline and T¼ 1 month.
**0.01P 0.05 for SPA group between baseline and T¼ 1 month.
***P<0.01 for difference between SPA and CTL group.
****0.01P 0.05 for difference between SPA and CTL group.
544 T. R. Zijlstra et al.
 at Universiteit Twente on April 23, 2010 
http://rheum
atology.oxfordjournals.org
D
ow
nloaded from
 
once subjects become accustomed to tender point assessments, they
tend to respond less.
Although there are no gold standards for improvement
in FM, some of our results can be compared with data from
other studies. First, in various chronic pain disorders, including
FM, a two-point reduction or a 30% improvement on an 11-point
numerical pain rating scale represents a clinically important
difference (defined as a patient global impression of ‘much
improved’ or ‘very much improved’) [48]. Assuming that the
same applies to a 100-mm VAS pain, the 27% improvement
observed after thalassotherapy indeed appears to be clinically
relevant. Second, in a study on responsiveness of outcome
measures for FM, ‘general improvement’ (as judged by patients
after 6 months) corresponded to a mean reduction of FIQ total
score by 15.8 points [31]. In our study the mean initial reduction
after thalassotherapy was 12.8 points (30% from baseline), again
indicating relevant improvement. Third, our results are better
than those reported for other combined treatment programmes:
9% improvement of FIQ total score after six sessions of patient
education and six sessions of exercise instructions [9], 25% after
6 months of weekly group therapy [10] and 14% after 6 months
of hydrotherapy and six education meetings [49].
Despite the initial size of the treatment effect, its temporary
nature raises questions about cost-effectiveness, which should
be addressed before implementing this programme. Furthermore,
one should ask what the additional effect of such a programme
is, compared with conventional exercise and patient education.
Our study does not provide definite answers to this question,
but some remarks can be made. It seems plausible to suggest
that a warm, dry and sunny climate may improve FM symptoms,
since a majority of FM patients report that their symptoms
are influenced by weather conditions [50, 51]. In contrast with
these patient impressions, formal studies on the relationship
between weather conditions and fibromyalgia found hardly any
correlation [52–55]. However, these studies focused on weather
changes within the same climate, whereas transition to a totally
different climate may influence FM symptoms more strongly.
Several additional factors might contribute to the overall beneficial
effect, such as a relaxing environment, support from other patients
and absence of work duties. The importance of such factors was
mentioned by Neumann et al. [19], who reported that FM patients
staying at the Dead Sea but not receiving balneotherapy still
showed significant improvement. A similar comment was made
by the authors of a recent study on spa-exercise therapy in
ankylosing spondylitis [56]. On the other hand, both studies
reported additional improvement in the spa or balneotherapy
group compared with controls, indicating that apart from the
non-specific ‘holiday effect’ there is also a specific treatment effect
involved.
In conclusion, a combination of thalassotherapy, exercise and
patient education can produce significant subjective improvement
in patients with FM, lasting for 3–6 months.
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